Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences reports positive clinical data for combination HIV therapy

Gilead Sciences reports positive clinical data for combination HIV therapy

5th October 2017

Gilead Sciences has announced new clinical trial data that highlights the strong performance offered by its newest combination HIV therapy.

New 48-week results from the phase III Study 1878 trial have demonstrated the efficacy and safety of switching virologically suppressed HIV-1 infected adult patients from a multi-tablet regimen containing a boosted protease inhibitor to a fixed-dose combination of bictegravir and emtricitabine/tenofovir alafenamide.

The combination regimen was shown to be statistically non-inferior to regimens containing boosted protease inhibitor, with no treatment-emergent resistance emerging after 48 weeks.

Gilead has already applied for regulatory approval of this new regimen in the US and EU, with a full response from the US Food and Drug Administration expected in February 2017.

Dr Norbert Bischofberger, Gilead's executive vice-president for research and development and chief scientific officer, said: "We look forward to the opportunity to offer patients this next-generation therapy as part of our TAF-based portfolio of treatments for HIV."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.